Protein biosynthesis, a target of sorafenib, interferes with the unfolded protein response (UPR) and ferroptosis in hepatocellular carcinoma cells

Sorafenib is the first line treatment for advanced hepatocellular carcinoma (HCC). We explored its impact on the proteostasis of cancer cells, i.e. the processes that regulate the synthesis, maturation and turn-over of cellular proteins. We observed that sorafenib inhibits the production of the tumo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Sauzay, Chloé, Louandre, Christophe, Bodeau, Sandra, Anglade, Frédéric, Godin, Corinne, Saidak, Zuzana, Fontaine, Jean-Xavier, Usureau, Cédric, Martin, Nathalie, Molinie, Roland, Pascal, Julie, Mesnard, François, Pluquet, Olivier, Galmiche, Antoine
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5823558/
https://ncbi.nlm.nih.gov/pubmed/29492203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23843
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados